ALPS Advisors
RPRX icon

ALPS Advisors’s Royalty Pharma RPRX Stock Holding History

ALPS Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$269K Sell
4,608
-310,727
-99% -$18.3M ﹤0.01% 1084
2026
Q2 		$17.7M Sell
315,335
-181,347
-37% -$9.44M 0.08% 140
2026
Q1 		$23.8M Sell
496,682
-24,101
-5% -$1.06M 0.11% 118
2025
Q4 		$20.1M Sell
520,783
-32,341
-6% -$1.23M 0.12% 125
2025
Q3 		$19.5M Buy
+553,124
New +$20M 0.11% 134
2024
Q3 		– Sell
-11,488
Closed -$303K – 1114
2024
Q2 		$303K Sell
11,488
-62
-0.5% -$1.72K ﹤0.01% 841
2024
Q1 		$351K Buy
+11,550
New +$340K ﹤0.01% 832
2021
Q3 		– Sell
-7,232
Closed -$296K – 1005
2021
Q2 		$296K Hold
7,232
– – ﹤0.01% 839
2021
Q1 		$315K Buy
+7,232
New +$343K ﹤0.01% 796

Other funds holding RPRX

Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $53.6B AUM 32.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Achmea Investment Management
Achmea Investment Management Zeist, Netherlands $12.6B AUM 25.68% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

ALPS Advisors's RPRX Position: Q3 2026 in Review

ALPS Advisors reduced its Royalty Pharma (RPRX) stake by 99% in Q3 2026, selling an estimated $18.3M and leaving 4,608 shares worth $269K. The position accounts for ﹤0.01% of the portfolio, ranked #1084.

ALPS Advisors first reported a position in RPRX in Q1 2021 and has held it in 9 quarters since. The position peaked at $23.8M in Q1 2026. 270 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

  • ALPS Advisors held 4,608 shares of Royalty Pharma worth $269K as of Q3 2026.
  • ALPS Advisors sold 310,727 Royalty Pharma shares in Q3 2026, an estimated $18.3M.
  • Royalty Pharma made up ﹤0.01% of ALPS Advisors's portfolio in Q3 2026, its #1084 holding.
  • ALPS Advisors first reported a position in Royalty Pharma in Q1 2021 and has held it in 9 quarters since.
  • ALPS Advisors's Royalty Pharma position peaked at $23.8M in Q1 2026.
  • 270 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on ALPS Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.